(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 14 December 2000 (14.12.2000)

(10) International Publication Number WO 00/75658 A2

(51) International Patent Classification7:

(21) International Application Number: PCT/NO00/00200

(22) International Filing Date: 8 June 2000 (08.06.2000)

(25) Filing Language:

English

G01N 33/53

(26) Publication Language:

English

(30) Priority Data: 19992786

8 June 1999 (08.06.1999) NO

- (71) Applicant (for all designated States except US): UNI-FOB, STIFTELSEN UNIVERSITETSFORSKNING BERGEN [NO/NO]; Prof. Keysersgt. 8, N-5007 Bergen (NO).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SKEIE, Geir, Olve [NO/NO]; Gørbitsgt. 1, N-5035 Bergen (NO). ZORZATO, Francesco [IT/IT]; Via Vittoria, 21, I-44100 Ferrara (IT).

- (74) Agent: AS BERGEN PATENTKONTOR; C. Sundtsgt. 36, N-5004 Bergen (NO).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(54) Title: DETECTION OF RYANODINE RECEPTOR ANTIBODIES

(57) Abstract: The present invention describes methods, kits and compositions for the detection of ryanodine receptor antibodies in patient serum samples. The invention also describes a method for the manufacture of a pharmaceutical agent for the prevention and/or treatment of the disease myasthenia gravis, and a method of myasthenia gravis prognosis.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 14 December 2000 (14.12.2000)

(10) International Publication Number WO 00/75658 A3

(51) International Patent Classification7: G01N 33/564, A61K 38/17, C07K 16/28, 14/435

(21) International Application Number: PCT/NO00/00200

(22) International Filing Date: 8 June 2000 (08.06.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 19992786

8 June 1999 (08.06.1999)

(71) Applicant (for all designated States except US): UNI-FOB, STIFTELSEN UNIVERSITETSFORSKNING BERGEN [NO/NO]; Prof. Keysersgt. 8, N-5007 Bergen (NO).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SKEIE, Geir, Olve [NO/NO]; Gørbitsgt. 1, N-5035 Bergen (NO). ZORZATO, Francesco [IT/IT]; Via Vittoria, 21, I-44100 Ferrara (IT).

(74) Agent: AS BERGEN PATENTKONTOR; P.O. Box 1998, Nordnes, N-5817 Bergen (NO).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

With international search report.

(88) Date of publication of the international search report: 28 June 2001


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.





(57) Abstract: The present invention describes methods, kits and compositions for the detection of ryanodine receptor antibodies in patient serum samples with the aid of N-terminal fragments of the receptor. The invention also describes a method for the manufacture of a pharmaceutical agent comprising such fragments for the prevention and/or treatment of the disease myasthenia gravis, and a method of myasthenia gravis prognosis.

INTERNATIONAL SEARCH REPORT



A. CLASSIFICATION OF SUBJECT MATTER 1PC 7 G01N33/564 A61K38/17

C07K16/28

C07K14/435

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\label{lower model} \begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{G01N} & \mbox{A61K} & \mbox{C07K} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)


EPO-Internal

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ASE MYGLAND ET AL: "Anti-cardiac ryanodine receptor antibodies in thymoma-associated myasthenia gravis" AUTOIMMUNITY, vol. 17, 1994, pages 327-331, XP002901348 page 330	1-6,8
A	ASE MYGLAND ET AL: "Thymomas express epitopes shared by the ryanodine receptor" JOURNAL OF NEUROIMMUNOLOGY, vol. 62, 1995, pages 79-83, XP002901349 page 80 page 82 -page 83	1-8

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.		
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member cf the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search report		
31 October 2000	1 5. 12. 00		
Name and mailing address of the ISA	Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Carl-Olof Gustafsson		

2





C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT							
ategory °							
Ą	GEIR OLVE SKEIE ET AL: "Autoimmunity to ryanodine receptor and titin in myasthenia gravis is associated with GM allotypes" AUTOIMMUNITY, vol. 26, 1997, pages 111-116, XP002901350 the whole document	1-8					
4	ASE MYGLAND ET AL: "Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma" ANN NEUROL, vol. 32, 1992, pages 589-591, XP002901351 the whole document	1-8					
	CHEMICAL ABSTRACTS, vol. 130, no. 6, 8 February 1999 (1999-02-08) Columbus, Ohio, US; abstract no. 62650, LEONG, PENG ET AL: "The cytoplasmic loops between domains II and III and domains III and IV in the skeletal muscle dihydropyridine receptor bind to a contiguous site in the skeletal muscle ryanodine receptor" page 1; XP002901352 abstract & J.BIOL.CHEM., 273(45),29958-29964, 1998,	1-6,8					
•	CHEMICAL ABSTRACTS, vol. 129, no. 3, 20 July 1998 (1998-07-20) Columbus, Ohio, US; abstract no. 24678, LEONG, PENG ET AL: "A 37-amino acid sequence in the skeletal muscle ryanodine receptor interacts with the cytoplasmic loop between domains II and III in the skeletal muscle dihydropyridine receptor" XP002901353 abstract & J.BIOL.CHEM.,273(14), 7791-7794, 1998,	1-6,8					
1	DE 197 22 317 C (BOEHRINGER INGELHEIM INT) 8 October 1998 (1998-10-08) page 7						
	US 5 358 649 A (MACLENNAN DAVID H ET AL) 25 October 1994 (1994-10-25) column 25 -column 27	1-6,8					

2



7208

International application No.

PCT/NO 00/00200

Information on patent family members 03/10/00

DE	19722317	C1	08/10/98	EP	0984986 A	15/03/00
				WO	9854212 A	03/12/98
US	5358649	Α	25/10/94	AU	665178 B	21/12/95
				DE	69108568 D,T	14/12/95
				EP	0563144 A,B	06/10/93
				ΑT	12 0 488 T	15/04/95
				AU	9103891 A	22/07/92
				CA	2064091 A,C	22/06/92
				CA	2079702 A	22/06/92
				DE	563144 T	03/02/94
				DK	563144 T	28/08/95
				ES	2072749 T	16/07/95
				GB	9027869 D	00/00/00
				ΙE	67816 B	01/05/96
				NZ	241112 A	27/09/93
				US	6001976 A	14/12/99
				WO	9211387 A	09/07/92
				ZA	9110087 A	28/10/92
				GB	9110865 D	00/00/00
				GB	9119250 D	00/00/00